What future means to management of blood centres

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 115-118

  Van Aken, W G ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BANK; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; FUTUROLOGY; INFECTION RISK; MANAGEMENT; PRIORITY JOURNAL; QUALITY CONTROL; SAFETY; TECHNOLOGY; VIRUS TRANSMISSION;

EID: 0031824634     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05407.x     Document Type: Conference Paper

References (14)

1. Institute of Medicine Committee to Study HIV Transmission Through Blood and Blood Products, HIV and the Blood Supply: An Analysis of Crisis Decisionmaking Editors: Leveton LB, Sox HC, Stoto MA: National Academy Press, Washington, DC (USA) 1995.
2. Blood Supply: FDA Oversight and Remaining Issues of Safety , United States General Accounting Office, Washington DC GAO/PEMD-97-1/2.
3. Commission of Inquiry on the Blood System in Canada, Final Report, Vol.1 - 3, Canadian Government Publishing, 1997.
4. Lohmann W, Schmidbauer H, Schnittler C: Zweite Beschluszempfehlung und Schluszbericht des 3. Untersuchungsaussschusses nach Artikel 44 de Grundgesetzes. Deutscher Bundestag
5. Wahlperiode, Drucksache 12/8591, 1994.
6. De Nationale Ombudsman, Openbaar rapport 95/271, The Hague, The Netherlands 1995.
7. AuBuchon JP: The role of decision analysis in transfusion medicine. Vox Sang. 1996; 71: 1-5.
8. AuBuchon JP, Birkmeyer JD, Busch MP: Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127: 904 - 909.
9. Sackett DL, Rosenberg WMC., Gray JAM, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isn't. Brit Med J 1996; 312: 71 - 72.
10. Sirchia G, Rebulla P: Evidence-based medicine: the case for white cell reduction, Transfusion 1996; 37: 534 - 549.
11. Barbara J, Flanagan P: Blood transfusion risk: protecting against the unknown, Worries over variant CJD should not detract from work on other, better known risks, BMJ 1998; 316: 717-718.
12. Lenny LL, Hurst R, Zhu A, Goldstein J: Multiple -unit and second transfusions of red cells enzymatically converted from group B to group O, Transfusion 1995; 35: 899 - 902.
13. Van Aken WG: The potential impact of recombinant factor VIII on haemophilia care and the demand for blood and blood products, Transf Med Rev 1997; 11: 6-14.
14. Paleyanda RK, Velander WH, Lee TK, Scandella DH et al: Transgenic pigs produce functional human factor VIII in milk, Nature Biotech 1997; 15: 971 - 975.